Compare AGMH & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGMH | MBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.1M |
| IPO Year | 2017 | 2023 |
| Metric | AGMH | MBIO |
|---|---|---|
| Price | $0.80 | $0.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 771.4K | 20.1K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.47 |
| 52 Week High | $11.74 | $1.84 |
| Indicator | AGMH | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 40.08 |
| Support Level | N/A | N/A |
| Resistance Level | $1.18 | $0.56 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 34.58 | 50.52 |
AGM Group Holdings Inc is a technology company engaged in technology hardware research and development, manufacturing, assembly, and sales. Its core business segments include research and development of blockchain-oriented ASIC chips, production of high-end crypto miners for Bitcoin and other cryptocurrencies, and Fintech software services. The Company mainly derives revenue from the sales of cryptocurrency mining machines and standardized computing equipment.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.